A Clinical Study of SPH9788 Tablets in Healthy Chinese Subjects.

NCT06839131 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2026-05-05

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety of SPH9788 tablets in healthy subjects.

Conditions

  • Healthy Participants

Interventions

DRUG

SPH9788

SPH9788 tablets administered orally

DRUG

Placebo

Matching placebo administered orally

Sponsors & Collaborators

  • Shanghai Pharmaceuticals Holding Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-02
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06839131 on ClinicalTrials.gov